Training and resources – doravirine▼ case studies

DELSTRIGO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Doravirine experience shared by Dr Graeme Moyle, HIV Physician at Chelsea & Westminster Hospital

Case study 1 : a case of a 37-year-old black female who has recently been diagnosed

DELSTRIGO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Jump to:

• Considerations for doravirine
• Case presentation 1
• Summary of doravirine efficacy and safety clinical trials
• DRIVE AHEAD wk 48 and 96: efficacy outcomes
• DRIVE AHEAD wk 48: neuropsychiatric adverse events
• DRIVE AHEAD & DRIVE FORWARD wk 48: lipid changes
• Effects on lipid changes from SPRING-2 wk 48
• Effects on lipid changes from STARTMRK wk 48
• Weight change: pooled analysis of doravirine treatment-naïve trials
• NA-ACCORD cohort study: weight gain by class or specific INSTIs
• Weight increase in the ADVANCE study wk 96
• DRIVE AHEAD & DRIVE FORWARD wk 48: treatment emergent drug resistance?
• Why DOR/TDF/3TC for case 1
• Summary

Case study 2: a case of a 42-year-old male of African origin on a first-generation NNRTI

DELSTRIGO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Jump to:

• Considerations for doravirine
• Case presentation 2
• Drive-Shift data design
• Primary and secondary outcome measures
• Efficacy analysis
• 144 weeks efficacy data
• Improvement in efficacy related symptoms
• Drive-Shift lipid data
• Drive-Shift mean adjusted weight change after switch to doravirine
• Summary

Case study 3: a case of a 57-year-old white male who was diagnosed 15 years ago and on a first-generation NNRTI

DELSTRIGO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Jump to:

• Considerations for doravirine
• Case presentation 3
• Key characteristics of NNRTIs
• Drug interactions with INSTIs and NNRTIs
• Doravirine or rilpivirine
• Key characteristics of doravirine vs. INSTI STRs
• Summary

Abbreviations

AEs: Adverse Events;
ARV OD: Antiretroviral Once Daily;
ART: Antiretroviral Treatment;
BD: Twice A Day;
BIC: Bictegravir;
BMD: Bone Mineral Density;
BMI: Body Mass Index;
CAC: Coronary Artery Calcium;
CI: Confidence Interval;
CNS: Central Nervous System;
DOR: Doravirine;
DTG: Dolutegravir;
EACS: European AIDS Clinical Society;
EFV: Efavirenz;
EVG: Elvitegravir;
FH: Familial Hypercholesterolemia;
FTC: Emtricitabine;
HLA: Human Leukocyte Antigen;
INSTI: Integrase Inhibitor;
IQR: Interquartile Range;
LFTs: Liver Function Tests;
MEC: Minimum Effective Concentration;
NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors;
OCP: Oral Contraceptive Pill;
OTC: Over The Counter;
PDVF: Protocol-Defined Virologic Failure;
PI: Protease Inhibitor;
PK: Pharmacokinetics;
PPIs: Proton Pump Inhibitors;
PLWH: People Living With HIV;
RAL: Raltegravir;
RPV: Rilpivirine;
SH: Social History;
SmPC: Summary Of Product Characteristics;
STR: Single-Tablet Regimen;
TAF: Tenofovir Alafenamide Fumarate;
TC: Total Cholesterol;
TDF: Tenofovir Disoproxil Fumarate;
WT: Wild Type;
VF: Virologic Failure;
VL: Viral Load;
3TC: Lamivudine

Supporting documentation

DELSTRIGO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
PIFELTRO^®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-DOR-00228 | Date of Preparation: January 2022